View in EDS

Proteasome subunit PSMD1 is a key therapeutic target in multiple myeloma.

Saved in:
Bibliographic Details
Title: Proteasome subunit PSMD1 is a key therapeutic target in multiple myeloma.
Authors: Du T; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Fang T; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Pillai S; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Ray A; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Wang M; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Wan X; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Wen K; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Liu Y; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Xu J; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Musa MA; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Liu X; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Fulciniti M; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Munshi NC; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.; VA Boston Healthcare System, Boston, MA., Garbicz F; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA., Carrasco RD; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA., Yao Y; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.; Blood Disease Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China., Zhang Z; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.; Department of Pharmacology, Jiangsu Provincial Key Laboratory of Critical Care Medicine, School of Medicine, Southeast University, Nanjing, China., Song Y; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Anderson KC; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.
Source: Blood [Blood] 2026 May 14; Vol. 147 (20), pp. 2344-2357.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41632828
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Proteasome subunit PSMD1 is a key therapeutic target in multiple myeloma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Du+T%22">Du T</searchLink>; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Fang+T%22">Fang T</searchLink>; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Pillai+S%22">Pillai S</searchLink>; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Ray+A%22">Ray A</searchLink>; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Wang+M%22">Wang M</searchLink>; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Wan+X%22">Wan X</searchLink>; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Wen+K%22">Wen K</searchLink>; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Liu+Y%22">Liu Y</searchLink>; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Xu+J%22">Xu J</searchLink>; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Musa+MA%22">Musa MA</searchLink>; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Liu+X%22">Liu X</searchLink>; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Fulciniti+M%22">Fulciniti M</searchLink>; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Munshi+NC%22">Munshi NC</searchLink>; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.; VA Boston Healthcare System, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Garbicz+F%22">Garbicz F</searchLink>; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Carrasco+RD%22">Carrasco RD</searchLink>; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Yao+Y%22">Yao Y</searchLink>; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.; Blood Disease Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China.<br /><searchLink fieldCode="AU" term="%22Zhang+Z%22">Zhang Z</searchLink>; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.; Department of Pharmacology, Jiangsu Provincial Key Laboratory of Critical Care Medicine, School of Medicine, Southeast University, Nanjing, China.<br /><searchLink fieldCode="AU" term="%22Song+Y%22">Song Y</searchLink>; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Anderson+KC%22">Anderson KC</searchLink>; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227603509%22">Blood</searchLink> [Blood] 2026 May 14; Vol. 147 (20), pp. 2344-2357.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7603509 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1528-0020 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200064971%22">00064971 </searchLink><i>NLM ISO Abbreviation: </i>Blood <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41632828
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/blood.2025029358
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2344
    Titles:
      – TitleFull: Proteasome subunit PSMD1 is a key therapeutic target in multiple myeloma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Du T
      – PersonEntity:
          Name:
            NameFull: Fang T
      – PersonEntity:
          Name:
            NameFull: Pillai S
      – PersonEntity:
          Name:
            NameFull: Ray A
      – PersonEntity:
          Name:
            NameFull: Wang M
      – PersonEntity:
          Name:
            NameFull: Wan X
      – PersonEntity:
          Name:
            NameFull: Wen K
      – PersonEntity:
          Name:
            NameFull: Liu Y
      – PersonEntity:
          Name:
            NameFull: Xu J
      – PersonEntity:
          Name:
            NameFull: Musa MA
      – PersonEntity:
          Name:
            NameFull: Liu X
      – PersonEntity:
          Name:
            NameFull: Fulciniti M
      – PersonEntity:
          Name:
            NameFull: Munshi NC
      – PersonEntity:
          Name:
            NameFull: Garbicz F
      – PersonEntity:
          Name:
            NameFull: Carrasco RD
      – PersonEntity:
          Name:
            NameFull: Yao Y
      – PersonEntity:
          Name:
            NameFull: Zhang Z
      – PersonEntity:
          Name:
            NameFull: Song Y
      – PersonEntity:
          Name:
            NameFull: Anderson KC
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 14
              M: 05
              Text: 2026 May 14
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1528-0020
          Numbering:
            – Type: volume
              Value: 147
            – Type: issue
              Value: 20
          Titles:
            – TitleFull: Blood
              Type: main
ResultId 1